Nebenwirkungen · Vaxneuvance
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 7
HOS-147686 · Präparat HOS-099718
The most frequent adverse reactions are injection-site pain (55%), myalgia (24%), injection-site swelling (21%), injection-site erythema (19%), fatigue (16%), headache (12%), injection-site induration (7%), and pyrexia ≥38 C (6%). The majority of adverse reactions were mild to moderate (based on intensity or size) and of short duration (≤3 days); severe reactions (defined as being extremely distressed or unable to do usual activities or size of injection-site reaction >8 cm) occurred in ≤5% of children and adolescents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T14:19:00Z · SHA-256 8c806efad2c6480965326c02c35aa390b1a5f1070feca6a9495a17a403d294b7 · Passage 724c488ad0f640e9ab92047e8f3112f309793f1f05d4e0e1af4f965818ac21b5 · Zeichen 1555–2079 im Abschnitt